drugset / Trial / NCT03191305

Comparison of the Efficacy of Rivroxaban to Coumadin( Warfarin ) in Cerebral Venous Thrombosis

NCT03191305

Non-randomizedParallel-groupSingle-blindHealth-services research

Summary

In past few years new anticoagulants have been developed which directly inhibit thrombin or factor X.factor x inhibitor is available in Pakistan. The superior efficacy of Rivroxaban has been shown in Deep Venous Thrombosis in EINSTEIN study (3).Its definite superiority in prevention of embolic stroke in nonvalvular atrial fibrillation is evidenced by the study ROCKET AF (4). With Rivroxaban no monitoring is required, and also there are no drug interactions .There are few pilot studies of using Rivroxaban in cerebral venous thrombosis. This study is therefore required to find its efficacy in CVT patients as well as its comparison with Coumadin

Timeline

Start
2017-08
Primary completion
2018-09
Completion
2018-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator Rivoroxaban Unknown 20 mg Oral
Comparator Warfarin Small molecule Oral